New Low-Dose Combination Therapy Blocks Cancer Metastasis in Mice
May 12, 2021
The main obstacles that lead to clinical failure in cancer treatment are the development of resistance to chemotherapy and a rise in invasive characteristics in cancer tumor cells due to prolonged chemotherapeutic processes. A new mouse study reveals that low doses of a four-drug combination help prevent the spread of cancer without triggering drug resistance or recurrence by simultaneously targeting multiple pathways within a metastasis-promoting network.
The findings are published in the journal
eLife in a paper titled, “Limited inhibition of multiple nodes in a driver network blocks metastasis,” and led by researchers at the University of Chicago, the University of São Paulo in Brazil, the University of North Carolina, and the University of Texas Southwestern Medical Center.
Low dose of a four-drug combination helps prevent cancer metastasis in mice
Low dose of a four-drug combination helps prevent the spread of cancer in mice without triggering drug resistance or recurrence, shows a study published today in
eLife.
The findings suggest a new approach to preventing cancer metastasis in patients by simultaneously targeting multiple pathways within a metastasis-promoting network. They may also help identify people who would most likely benefit from such treatment.
Metastasis, the spread of cancerous cells through the body, is a common cause of cancer-related deaths. Current approaches to treating metastatic cancer have focused on high doses of individual drugs or drug combinations to hinder pathways that promote the spread of cancer cells. But these approaches can be toxic to the patient, and may inadvertently activate other pathways that cause the drugs to stop working and the tumors to return.
E-Mail
Low doses of a four-drug combination helps prevent the spread of cancer in mice without triggering drug resistance or recurrence, shows a study published today in
eLife.
The findings suggest a new approach to preventing cancer metastasis in patients by simultaneously targeting multiple pathways within a metastasis-promoting network. They may also help identify people who would most likely benefit from such treatment.
Metastasis, the spread of cancerous cells through the body, is a common cause of cancer-related deaths. Current approaches to treating metastatic cancer have focused on high doses of individual drugs or drug combinations to hinder pathways that promote the spread of cancer cells. But these approaches can be toxic to the patient, and may inadvertently activate other pathways that cause the drugs to stop working and the tumours to return.